Cancer Nanotechnology

Cancer Nanotechnology is an open access journal published by Springer Nature, founded in 2010, covering nanostructures and nanoscale processes for the prevention, diagnosis and treatment of cancer, with a 2025 Journal Impact Factor of 5.8.《癌症纳米技术》（Cancer Nanotechnology）由（Springer Nature）出版，2010 年创刊，为开放获取期刊，刊载用于癌症预防、诊断与治疗的纳米结构与纳米尺度过程研究，2025 年期刊影响因子为 5.8。

Scope

• Nanoparticle design, synthesis and surface engineering for tumour-targeted drug delivery form the core of the journal.面向肿瘤靶向递药的纳米颗粒设计、合成与表面工程，是期刊的核心内容。
• Cancer imaging and diagnosis are covered, including multimodal probes, image-guided therapy and liquid-biopsy nanostructures.癌症成像与诊断，包括多模态探针、影像引导治疗与用于液体活检的纳米结构。
• Nano-immunotherapy, from nano-vaccines to immune checkpoint modulation by nanomaterials, has become a major stream.纳米免疫治疗，从纳米疫苗到以纳米材料调控免疫检查点，已成为主要方向。
• Radiotherapy and radio-nanomaterials, including radiosensitisation and radionuclide delivery, are within scope.放射治疗与放射性纳米材料，包括放射增敏与放射性核素递送，属于收稿范围。
• Nanosystems that remodel the tumour microenvironment, such as those targeting hypoxia, stroma or the extracellular matrix, are published.重塑肿瘤微环境的纳米体系，例如靶向乏氧、基质或细胞外基质者，均在刊载之列。
• Biocompatibility, toxicity, pharmacokinetics and the translational pharmacology of nanomaterials are treated as integral rather than optional.纳米材料的生物相容性、毒性、药代动力学与转化药理学，被视为必要组成部分而非可选项。
• Article types include Research, Review and short communications, and the journal is a companion title to Journal of Nanobiotechnology.文章类型包括研究论文、综述与短篇通讯，本刊为（Journal of Nanobiotechnology）的姊妹刊。

History

• The first papers appeared in 2010 under Springer-Verlag Wien, and the journal has published a single volume a year since.首批论文于 2010 年在（Springer-Verlag Wien）出版，此后每年一卷。
• It was set up as a dedicated venue for the then young interface between nanotechnology and oncology, at a time when most nanomedicine appeared in general materials journals.期刊创立时纳米技术与肿瘤学的交叉尚属新兴，多数纳米医学论文分散于通用材料类期刊，本刊因此定位为专门园地。
• Publication moved to the BMC platform within Springer Nature, with continuous article numbering in place of issue pagination.出版已迁至（Springer Nature）旗下的（BMC）平台，采用连续文章编号而非按页编排。
• It belongs to a nanobiotechnology companion family that also includes Journal of Nanobiotechnology, Health Nanotechnology and Bioscience Nanotechnology.本刊属于纳米生物技术姊妹刊群，同群还包括（Journal of Nanobiotechnology）、（Health Nanotechnology）与（Bioscience Nanotechnology）。
• The 2025 Journal Impact Factor is 5.8, against 4.8 in 2024, 7.917 in 2022 and 5.095 in 2021.2025 年期刊影响因子为 5.8，2024 年为 4.8，2022 年为 7.917，2021 年为 5.095。
• In the 2025 Journal Citation Reports it is first quartile in oncology at 67th of 333, and second quartile in nanoscience and nanotechnology.在 2025 年期刊引证报告中，本刊于肿瘤学类 333 种期刊中位列第 67，属第一四分位，在纳米科学与技术类属第二四分位。

Editors

• Hao Hong, professor at the medical school of Nanjing University, is editor-in-chief.南京大学医学院教授 Hao Hong 任主编。
• His research concerns radioligands for positron emission tomography and metal-coordination nanoplatforms for theranostics, chiefly with zirconium-89, copper-64 and lutetium-177.他的研究集中于正电子发射断层显像用放射性配体，以及用于诊疗一体的金属配位纳米平台，主要涉及锆 89、铜 64 与镥 177。
• Hong previously worked as a research assistant professor of radiology at the University of Michigan and as a postdoctoral fellow at the University of Wisconsin-Madison.Hong 此前在密歇根大学任放射学研究助理教授，并在威斯康星大学麦迪逊分校从事博士后研究。
• A dedicated international editorial board supports the in-house editors and gives what the journal describes as thorough but swift editorial response.专门的国际编委会支持社内编辑，官方称其提供周全而迅速的编辑处理。
• The median time to first decision is seven days, and manuscripts are assessed for translational potential as well as technical quality.初审中位时间为 7 天，稿件除技术质量外还须评估转化潜力。
• Review is single blind and all content is published open access under a CC BY licence, with an article processing charge payable on acceptance.评审为单盲，全部内容以 CC BY 许可开放获取，作者在录用后支付文章处理费。